The Federal Coordinating Council for Comparative Effectiveness Research and the Institute of Medicine (IOM) outlined to the US Department of Health and Human Services what they consider priorities for comparative effectiveness research.
The Federal Coordinating Council for Comparative Effectiveness Research outlined which interventions and populations should receive part of the $400 million being made available to HHS for comparative effectiveness research as part of the American Recovery and Reinvestment Act (ARRA) on Monday. Similarly, the IOM offered its suggestions yesterday about national priorities to be addressed by comparative effectiveness research.
The Recovery Act (ARRA) contains $1.1 billion for comparative effectiveness research. Comparative effectiveness research (CER) compares treatments and strategies to improve health. This information is essential for clinicians and patients to decide on the best treatment. It also enables our nation to improve the health of communities and the performance of the health system.
• $300 million for the Agency for Healthcare Research and Quality
• $400 million for the National Institutes of Health, and
• $400 million for the Office of the Secretary of Health and Human Services
These funds are to support research assessing the comparative effectiveness of health care treatments and strategies, through efforts that:
• Conduct, support, or synthesize research that compares the clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent, diagnose, or treat diseases, disorders, and other health conditions.
• Encourage the development and use of clinical registries, clinical data networks, and other forms of electronic health data that can be used to generate or obtain outcomes data.